Annovis Bio company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

annovisbio.com

Stage

IPO | IPO

Total Raised

$11.88M

Date of IPO

1/29/2020

Market Cap

0.07B

About Annovis Bio

Annovis Bio (NYSE: ANVS) is a clinical-stage, drug platform company addressing chronic and acute neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). Annovis' approach is to develop drugs that normalize the transport of information within and between nerve cells, called axonal transport. Its drug, ANVS-401, restores axonal transport and homeostasis in the brain by inhibiting the synthesis of neurotoxic proteins. Annovis has an ongoing Phase 2a proof-of-concept study in mild to moderate AD patients and a ready program to conduct a second Phase 2a study in PD patients.

Annovis Bio Headquarter Location

1055 Westlakes Drive Suite 300

Berwyn, Pennsylvania, 19312,

United States

610-727-3913

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Annovis Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Annovis Bio is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Annovis Bio Patents

Annovis Bio has filed 7 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Neurological disorders
  • Proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/8/2019

8/24/2021

Acetylcholinesterase inhibitors, Rare diseases, Psychiatric diagnosis, Monoclonal antibodies, Organophosphate insecticides

Grant

Application Date

7/8/2019

Grant Date

8/24/2021

Title

Related Topics

Acetylcholinesterase inhibitors, Rare diseases, Psychiatric diagnosis, Monoclonal antibodies, Organophosphate insecticides

Status

Grant

Latest Annovis Bio News

Annovis Bio reports Q1 results

May 4, 2022

Annovis Bio press release (NYSE: ANVS ): Q1 Net Loss of $5.9M Cash, cash equivalents, and marketable securities were $42.7 million as of March 31, 2022. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Annovis Bio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Annovis Bio Rank

  • Where is Annovis Bio's headquarters?

    Annovis Bio's headquarters is located at 1055 Westlakes Drive, Berwyn.

  • What is Annovis Bio's latest funding round?

    Annovis Bio's latest funding round is IPO.

  • How much did Annovis Bio raise?

    Annovis Bio raised a total of $11.88M.

  • Who are the investors of Annovis Bio?

    Investors of Annovis Bio include Metalmark Capital, Robin Hood Ventures, Delaware Crossing Investment Group, Michael Hoffman, Keiretsu Forum and 4 more.

  • Who are Annovis Bio's competitors?

    Competitors of Annovis Bio include Intarcia Therapeutics, Synapsin Pharmaceuticals, CoMentis, Hyperion Therapeutics, Neuronascent and 16 more.

You May Also Like

R
ROXRO Pharma

Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.

H
Humanetics Corporation

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.

Neurelis Logo
Neurelis

Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

N
NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.

Q
Q Therapeutics

Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.